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ABSTRACT
Aiming to deepen the structure–activity relationships of the two P-glycoprotein (P-gp) modulators elacri-
dar and tariquidar, a new series of amide and ester derivatives carrying a 6,7-dimethoxy-2-phenethyl-
1,2,3,4-tetrahydroisoquinoline scaffold linked to different methoxy-substituted aryl moieties were synthes-
ised. The obtained compounds were evaluated for their P-gp interaction profile and selectivity towards
the two other ABC transporters, multidrug-resistance-associated protein-1 and breast cancer resistance
protein, showing to be very active and selective versus P-gp. Two amide derivatives, displaying the best
P-gp activity, were tested in co-administration with the antineoplastic drug doxorubicin in different cancer
cell lines, showing a significant sensitising activity towards doxorubicin. The investigation on the chemical
stability of the derivatives towards spontaneous or enzymatic hydrolysis, showed that amides are stable in
both models while some ester compounds were hydrolysed in human plasma. This study allowed us to
identify two chemosensitizers that behave as non-transported substrates and are characterised by different
selectivity profiles.
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The chemotherapy against cancer is often undermined by resist-
ance that tumour cells develop to cytotoxic compounds after an
exposure period. Multidrug resistance (MDR) was described as
acquired resistance developed towards a multiplicity of structur-
ally unrelated chemotherapeutic drugs1, to which cells could also
have never been exposed2. The MDR phenotype is often related
to an enhanced energy-dependent drug efflux, elicited by the
overexpression of transmembrane proteins that extrude substrates
in a unidirectional way and reduce the concentration of antitumor
drugs below the active dose. In human MDR cells, these proteins
are part of the ATP-binding cassette (ABC) transporter family3,4,
and use the energy deriving from ATP hydrolysis for this
active transport.
In addition to be overexpressed in cancer cells, these proteins
are also present in many healthy tissues where they arouse differ-
ent physiological and pharmacological actions5, by regulating the
permeability of biological membranes. In fact, they are often
involved in the protection of these tissues from xenobiotics and
can influence ADME properties and bioavailability of many drugs.
The human genome encodes 49 ABC transmembrane proteins,
divided into seven subfamilies (ABC-A to ABC-G), based on the
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similarity of their amino acid sequences6. Three transport proteins:
P-glycoprotein (P-gp, ABCB1)7,8, multidrug-resistance-associated
protein-1 (MRP1, ABCC1)9,10, and breast cancer resistance protein
(BCRP, ABCG2)11,12 have mainly been associated with MDR13–15.
Studies on P-gp showed the first evidences of a relationship
between its overexpression and tumour responses to cytotoxic
drugs; then also MRP1 and BCRP overexpression16,17 was high-
lighted in different kind of tumours. Evidences also suggest that
these three pumps can be co-expressed18.
Since the discovery of P-gp, the identification of compounds
that act as inhibitors of P-gp and then of the sister proteins has
been considered a possible way to fight against MDR. These com-
pounds can be defined as chemo-sensitizers or MDR reversers;
they should restore the efficacy of cytotoxic agents in resistant
cancer cells if co-administered with the drugs which are substrates
of the transporters19.
A great number of compounds showing P-gp modulating activ-
ity has been synthesised and studied, and were classified as first,
second- or third-generation20,21 but none of these compounds
has overcome the clinical trials, because no substantial benefits
have been established. In fact, they often showed a low potency;
moreover, they interacted with CYP4503A4 and altered the phar-
macokinetic profiles of the co-administered antitumor agents,
leading therefore also to increased toxicity22,23, although some of
the latest MDR-reversing compounds show a safer profile.
Therefore, aiming to overcome the obstacles described above, the
search for safer ABC-transporter dependent MDR modulators is
still pursued.
Two of the most interesting third-generation chemo-sensitizers are
the tetrahydroisoquinoline derivatives elacridar (GF120918 or
GW120918)24 and tariquidar (XR9576)25. These compounds displayed
a high affinity towards the ABC proteins and a reduced effect on
cytochromes, and few pharmacokinetic interactions with the cytotoxic
drugs26. Disappointingly, clinical trials27 failed to show an improve-
ment of the efficacy of antitumor agents after co-administration of
these compounds28,29, and they have not been approved for therapy.
Elacridar and tariquidar share a common structural characteristic,
the presence of a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroiso-
quinoline moiety connected to an aryl substituted amide function
(Chart 1). Early studies indicated that both derivatives are not spe-
cific for P-gp because they are also able to bind the BCRP trans-
porter30. Subsequent structure-activity relationship studies suggested
that the 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline
nucleus is essential for inhibiting the two transporter proteins P-gp
and BCRP while changes at the aryl-substituted amide moiety elicit
variations in the selectivity31. In the case of tariquidar, recent eviden-
ces indicated that this molecule is able to bind also the MRP1 trans-
porter32; the same compound was shown to potentiate the
sensitivity to paclitaxel in resistant cells transfected by another mem-
ber of the ABCC family, the MRP7 protein33.
Therefore, despite the failure in clinical trials, tariquidar and
elacridar have been considered lead compounds in the search for
Figure 1. (A) Compounds described in the previous study34; (B) compounds synthesised in the present work.
Chart 1. Tariquidar and elacridar.
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new MDR modulators, and a large number of analogues of these
two derivatives have been synthesised.
Our research is part of this field of interest and aims to achieve
information about the structural characteristics that confer potency
and/or selectivity towards this family of transporters. In a previous
study34, we reported a new series of derivatives bearing the 6,7-
dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline moiety linked,
as elacridar and tariquidar, to an aryl substituted amide, on which
different aryl nucleus have been inserted (Figure 1); we also synthes-
ised the corresponding isosteric ester derivatives. The aryl residues
were selected based on their presence in other compounds bearing
different skeletons, acting as very potent MDR reversers35–40. The
obtained compounds were studied to evaluate their P-gp interaction
profile and selectivity towards MPR1 and BCRP, using Madin-Darby
Canine Kidney (MDCK) transfected cells.
Both amide and ester derivatives were active, although less
potent with respect to lead derivatives and, in general, more
selective towards P-gp. Interestingly, biological data indicated that
in these series of tetrahydroisoquinoline derivatives the presence
of an amide function was not essential for modulating the trans-
porter proteins; and the presence of an ester function in place of
an amide seemed to influence P-gp selectivity. As a continuation
of this study, aiming to better evaluate the features for selectivity
towards the three transporters and to deepen the structure–activ-
ity relationships of the series, we designed and synthesised a new
series of amide and ester derivatives characterised by the pres-
ence of a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline
scaffold linked to additional different aryl moieties (Figure 1). The
new aryl moieties are methoxy-substituted phenyl or naphthyl
nuclei, or nitrogen-containing hetero-aromatic residues.
The synthesised compounds were evaluated for their P-gp
interaction profile and selectivity towards the two other ABC
transporters, MPR1 and BCRP. The P-gp interacting-mechanism
was investigated combining three assays: (i) apparent permeability
(Papp) determination (BA/AB) in Caco-2 cell monolayer; (ii) ATP cell
depletion in cells overexpressing the transporter (MDCK-MDR1);
(iii) the inhibition of Calcein-AM transport in MDCK-MDR1 cells.
The activity on MRP1 and BCRP was evaluated on cancer cell lines
overexpressing each transporter (MDCK-MRP1 and MDCK-BCRP
cells), by measuring the inhibition of the efflux of the pro-fluores-
cent probe Calcein-AM in MDCK-MRP1 cells or the fluorescent
probe Hoechst 33342 in MDCK-BCRP cells.
Furthermore two selected compounds were further tested
alone and in co-administration with the antineoplastic drug doxo-
rubicin in different cancer cell lines with various levels of P-gp.
Finally, the stability of amide and ester derivatives was investi-
gated in phosphate buffer solution (PBS) and human plasma, and
the degradation profiles of the molecules were evaluated.
Material and methods
Chemistry
All melting points were taken on a B€uchi apparatus and are
uncorrected. NMR spectra were recorded on a Bruker Avance 400
spectrometer (400MHz for 1H-NMR, 100MHz for 13C-NMR). 1H and
13C NMR spectra were measured at room temperature (25 C) in
an appropriate solvent. 1H and 13C chemical shifts are expressed
in ppm (d) referenced to TMS. Spectral data are reported using
the following abbreviations: s¼ singlet, d¼doublet, dd¼doublet
of doublets, t¼ triplet, td¼ triplet of doublets, m¼multiplet, and
coupling constants are reported in Hz, followed by integration.
Chromatographic separations were performed on a silica gel
column by gravity chromatography (Kieselgel 40, 0.063–0.200mm;
Merck) or flash chromatography (Kieselgel 40, 0.040–0.063mm;
Merck). Yields are given after purification, unless otherwise stated.
The high resolution mass spectrometry (HRMS) analysis was
performed with a Thermo Finnigan LTQ Orbitrap mass spectrom-
eter equipped with an electrospray ionisation source (ESI). The
accurate mass measure was carried out by introducing, via syringe
pump at 10 lL min1, the sample solution (1.0lg mL1 in mQ
water: acetonitrile 50:50), and the signal of the positive ions was
acquired. The proposed experimental conditions allowed to moni-
toring the protonated molecules of studied compounds ([MþH]þ
species), that they were measured with a proper dwell time to
achieve 60,000 units of resolution at Full Width at Half Maximum
(FWHM). The elemental composition of compounds was calculated
on the basis of their measured accurate masses, accepting only
results with an attribution error less than 2.5 ppm and a not inte-
ger RDB (double bond/ring equivalents) value, in order to consider
only the protonated species41.
Compounds were named following IUPAC rules as applied by
ChemBioDraw Ultra 14.0 software. When reactions were per-
formed in anhydrous conditions, the mixtures were maintained
under nitrogen. Free bases 1–26 were transformed into the hydro-
chloride by treatment with a solution of acetyl chloride (1.1 eq) in
anhydrous CH3OH. The salts were crystallised from abs. ethanol/
petroleum ether.
General procedures for the synthesis of the amide
derivatives 1–13
Compounds were synthesised using two different gen-
eral procedures.
General procedure A. To a solution of the aniline 2734
(0.25mmol) in 5ml of an. CH2Cl2 or an. CH3CN at 0 C, the proper
carboxylic acid (0.30mmol), DMAP (0.20mmol) and EDC hydro-
chloride (0.45mmol) were added. The reaction mixture was stirred
at 0 C for 1 h, then at room temperature for 48 h. The mixture
was treated with CH2Cl2 and the organic layer was washed with
water and with a saturated solution of NaHCO3. After drying with
Na2SO4, the solvent was removed under reduced pressure. The
residue was then purified by flash chromatography using the
appropriate eluting system, obtaining the desired compound as
an oil.
General procedure B. The proper carboxylic acid (0.30mmol)
was transformed into the acyl chloride by reaction with SOCl2 (4
eq) in 5ml of CHCl3 (free of ethanol) or an. CH3CN at 60 C for
6–8 h. The reaction mixture was cooled to rt, and the solvent was
removed under reduced pressure. The mixture was then treated
twice with cyclohexane and the solvent removed under reduced
pressure. The acyl chloride obtained was dissolved in CHCl3 (free
of ethanol), and the aniline 2734 (0.25mmol) was added. The mix-
ture was kept at rt for 24 h, then the organic layer was washed
twice with a saturated solution of NaHCO3. After drying with
Na2SO4, the solvent was removed under reduced pressure. The
residue obtained was purified by flash chromatography using the
appropriate eluting system, yielding the desired compound as
an oil.
In both procedures A and B, all the compounds were trans-
formed into the corresponding hydrochloride as solid. The salts
were crystallised from abs. ethanol/petroleum ether.
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N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2,3,4-trimethoxybenzamide (1)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 2,3,4-trimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 15.1%.
1H NMR (400MHz, CDCl3) d: 9.92 (s, 1H, NH); 7.98 (d, J¼ 8.8 Hz,
1H, CH arom.); 7.60 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.23 (d, J¼ 8.4 Hz,
2H, CH arom.); 6.82 (d, J¼ 8.8 Hz, 1H, CH arom.); 6.60 (s, 1H, CH
arom.); 6.53 (s, 1H, CH arom.); 4.05 (s, 3H, OCH3); 3.92 (s, 3H,
OCH3); 3.90 (s, 3H, OCH3); 3.84 (s, 3H, OCH3); 3.83 (s, 3H, OCH3);
3.69 (s, 2H, NCH2Ar); 2.96–2.89 (m, 2H, CH2); 2.88–2.75 (m, 6H,
CH2) ppm.
13C NMR (100MHz, CDCl3) d: 162.71 (C¼O); 156.78 (C);
152.14 (C); 147.66 (C); 147.32 (C); 136.69 (C); 135.84 (C); 129.26 (CH
arom.); 126.96 (CH arom.); 125.97 (C); 125.91 (C); 120.33 (CH
arom.); 119.00 (C); 111.38 (CH arom.); 109.49 (CH arom.); 107.89
(CH arom.); 61.97 (OCH3); 61.05 (OCH3); 59.93 (CH2); 56.10 (OCH3);
55.95 (OCH3); 55.91 (OCH3); 55.46 (CH2); 50.91 (CH2); 33.24 (CH2);
28.35 (CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion spe-
cies C29H35N2O6¼ 507.2490, found 507.2492.
Hydrochloride: mp 208–211 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2-methoxybenzamide (2)
Procedure A in an. CH2Cl2, starting from aniline 27 and 2-methox-
ybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 88.9%.
1H NMR (400MHz, CDCl3) d: 9.71 (s, 1H, NH); 8.22 (d, J¼ 8.0 Hz,
1H, CH arom.); 7.56 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.41 (t, J¼ 8.0 Hz,
1H, CH arom.); 7.18 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.06 (t, J¼ 8.0 Hz,
1H, CH arom.); 6.95 (d, J¼ 8.0 Hz, 1H, CH arom.); 6.55 (s, 1H, CH
arom.); 6.49 (s, 1H, CH arom.); 3.96 (s, 3H, OCH3); 3.79 (s, 3H,
OCH3); 3.78 (s, 3H, OCH3); 3.60 (s, 2H, NCH2Ar); 2.90–2.67 (m, 8H,
CH2) ppm.
13C NMR (100MHz, CDCl3) d: 163.13 (C¼O); 157.19 (C);
147.59 (C); 147.27 (C); 136.50 (C); 136.09 (C); 133.16 (CH arom.);
132.39 (CH arom.); 129.17 (CH arom.); 126.29 (C); 126.06 (C);
121.83 (C); 121.59 (CH arom.); 120.58 (CH arom.); 111.57 (CH
arom.); 111.44 (CH arom.); 109.56 (CH arom.); 60.03 (CH2); 56.21
(OCH3); 55.95 (OCH3); 55.91 (OCH3); 55.56 (CH2); 50.96 (CH2); 33.33
(CH2); 28.53 (CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion
species C27H31N2O4¼ 447.2278, found 447.2279.
Hydrochloride: mp 226–228 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2,4-dimethoxybenzamide (3)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 2,4-dimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 54.7%.
1H NMR (400MHz, CDCl3) d: 9.69 (s, 1H, NH); 8.26 (d, J¼ 8.8 Hz,
1H, CH arom.); 7.60 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.23 (d, J¼ 8.4 Hz,
2H, CH arom.); 6.66 (dd, J¼ 8.8 Hz, 2.2 Hz, 1H, CH arom.); 6.62 (s,
1H, CH arom.); 6.55 (s, 1H, CH arom.); 6.54 (d, J¼ 2.2 Hz, 1H, CH
arom.); 4.03 (s, 3H, OCH3); 3.88 (s, 3H, OCH3); 3.86 (s, 3H, OCH3);
3.85 (s, 3H, OCH3); 3.73 (s, 2H, NCH2Ar); 3.00–2.94 (m, 2H, CH2);
2.93–2.77 (m, 6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 163.70
(C¼O); 163.04 (C); 158.51 (C); 147.66 (C); 147.31 (C); 136.78 (C);
135.43 (C); 134.16 (CH arom.); 129.18 (CH arom.); 125.71 (C);
120.57 (CH arom.); 114.67 (C); 111.27 (CH arom.); 109.38 (CH
arom.); 105.65 (CH arom.); 98.74 (CH arom.); 59.80 (CH2); 56.20
(OCH3); 55.93 (OCH3); 55.89 (OCH3); 55.59 (OCH3); 55.30 (CH2);
50.85 (CH2); 33.11 (CH2); 28.16 (CH2) ppm. ESI-HRMS (m/z) calcu-
lated for [MþH]þ ion species C28H33N2O5¼ 477.2384,
found 477.2379.
Hydrochloride: mp 233–235 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2,6-dimethoxybenzamide (4)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 2,6-dimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH 95:5.
Yield: 75.0%.
1H NMR (400MHz, CDCl3) d: 7.53 (d, J¼ 8.4 Hz, 2H, CH arom.);
7.50 (s, 1H, NH); 7.24 (t, J¼ 8.4 Hz, 1H, CH arom.); 7.15 (d,
J¼ 8.4 Hz, 2H, CH arom.); 6.55 (s, 1H, CH arom.); 6.53 (d, J¼ 8.4 Hz,
2H, CH arom.); 6.48 (s, 1H, CH arom.); 3.79 (s, 3H, OCH3); 3.78 (s,
3H, OCH3); 3.76 (s, 6H, OCH3); 3.63 (s, 2H, NCH2Ar); 2.90–2.70 (m,
8H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 163.65 (C¼O); 157.55
(C); 147.64 (C); 147.31 (C); 136.58 (C); 135.85 (C); 131.03 (CH
arom.); 129.13 (CH arom.); 125.91 (C); 119.82 (CH arom.); 116.00
(C); 111.39 (CH arom.); 109.52 (CH arom.); 104.11 (CH arom.); 59.92
(CH2); 56.02 (OCH3); 55.94 (OCH3); 55.90 (OCH3); 55.42 (CH2); 50.90
(CH2); 33.17 (CH2); 28.34 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C28H33N2O5¼ 477.2384, found 477.2384.
Hydrochloride: mp 212–214 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2,3-dimethoxybenzamide (5)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 2,3-dimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 65.6%.
1H NMR (400MHz, CDCl3) d: 9.93 (s, 1H, NH); 7.73 (dd, J¼ 8.0,
1.6 Hz, 1H, CH arom.); 7.58 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.20 (d,
J¼ 8.4 Hz, 2H, CH arom.); 7.15 (t, J¼ 8.0 Hz, 1H, CH arom.); 7.03
(dd, J¼ 8.0, 1.6 Hz, 1H, CH arom.); 6.56 (s, 1H, CH arom.); 6.50 (s,
1H, CH arom.); 3.93 (s, 3H, OCH3); 3.87 (s, 3H, OCH3); 3.80 (s, 3H,
OCH3); 3.79 (s, 3H, OCH3); 3.62 (s, 2H, NCH2Ar); 2.90–2.84 (m, 2H,
CH2); 2.83–2.69 (m, 6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d:
162.90 (C¼O); 152.61 (C); 147.57 (C); 147.25 (C); 147.20 (C); 136.51
(C); 136.28 (C); 129.29 (CH arom.); 126.93 (C); 126.40 (C); 126.10
(C); 124.74 (CH arom.); 122.93 (CH arom.); 120.28 (CH arom.);
115.70 (CH arom.); 111.40 (CH arom.); 109.52 (CH arom.); 61.65
(OCH3); 60.13 (CH2); 56.14 (OCH3); 55.94 (OCH3); 55.91 (OCH3);
55.64 (CH2); 51.00 (CH2); 33.40 (CH2); 28.62 (CH2) ppm. ESI-HRMS
(m/z) calculated for [MþH]þ ion species C28H33N2O5¼ 477.2384,
found 477.2375.
Hydrochloride: mp 230–233 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-1-naphthamide (6)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 1-naphthoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 53.6%.
1H NMR (400MHz, CDCl3) d: 8.29–8.27 (m, 1H, CH arom.); 7.95
(s, 1H, NH); 7.87 (d, J¼ 7.6 Hz, 1H, CH arom.); 7.84–7.81 (m, 1H, CH
arom.); 7.62 (d, J¼ 7.6 Hz, 1H, CH arom.); 7.56 (d, J¼ 8.4 Hz, 2H, CH
arom.); 7.51–7.46 (m, 2H, CH arom.); 7.38 (t, J¼ 7.6 Hz, 1H, CH
arom.); 7.19 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.56 (s, 1H, CH arom.);
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6.49 (s, 1H, CH arom.); 3.79 (s, 3H, OCH3); 3.78 (s, 3H, OCH3); 3.63
(s, 2H, NCH2Ar); 2.92–2.85 (m, 2H, CH2); 2.84–2.68 (m, 6H, CH2)
ppm. 13C NMR (100MHz, CDCl3) d: 167.58 (C¼O); 147.60 (C);
147.28 (C); 136.67 (C); 136.24 (C); 134.49 (C); 133.72 (C); 130.91 (CH
arom.); 130.10 (C); 129.31 (CH arom.); 128.40 (CH arom.); 127.27
(CH arom.); 126.53 (CH arom.); 126.28 (C); 126.07 (C); 125.30 (CH
arom.); 125.10 (CH arom.); 124.71 (CH arom.); 120.29 (CH arom.);
111.42 (CH arom.); 109.54 (CH arom.); 60.05 (CH2); 55.94 (OCH3);
55.90 (OCH3); 55.61 (CH2); 51.00 (CH2); 33.36 (CH2); 28.56 (CH2)
ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C30H31N2O3¼ 467.2329, found 467.2320.
Hydrochloride: mp 218–220 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2-methoxy-1-naphthamide (7)
Procedure A in an. CH2Cl2, starting from aniline 27 and 2-
methoxy-1-naphthoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH 95:5.
Yield: 30.5%.
1H NMR (400MHz, CDCl3) d: 7.99 (d, J¼ 8.0 Hz, 1H, CH arom);
7.84 (d, J¼ 8.8 Hz, 1H, CH arom.); 7.81 (s, 1H, NH); 7.75 (d,
J¼ 8.0 Hz, 1H, CH arom.); 7.60 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.44 (t,
J¼ 8.0 Hz, 1H, CH arom.); 7.33 (t, J¼ 8.0 Hz, 1H, CH arom.); 7.22 (d,
J¼ 8.8 Hz, 1H, CH arom.); 7.21 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.56 (s,
1H, CH arom.); 6.50 (s, 1H, CH arom.); 3.91 (s, 3H, OCH3); 3.80 (s,
3H, OCH3); 3.79 (s, 3H, OCH3); 3.63 (s, 2H, NCH2Ar); 2.95–2.86 (m,
2H, CH2); 2.85–2.69 (m, 6H, CH2) ppm.
13C NMR (100MHz, CDCl3)
d: 165.45 (C¼O); 153.71 (C); 147.60 (C); 147.28 (C); 136.45 (C);
131.57 (CH arom.); 129.28 (CH arom.); 128.85 (C); 128.03 (CH
arom.); 127.66 (CH arom.); 126.38 (C); 126.11 (C); 124.34 (CH
arom.); 124.25 (CH arom.); 120.51 (C); 120.07 (CH arom.); 113.08
(CH arom.); 111.44 (CH arom.); 109.57 (CH arom.); 60.12 (CH2);
56.77 (OCH3); 55.95 (OCH3); 55.91 (OCH3); 55.63 (CH2); 51.01 (CH2);
33.37 (CH2); 28.60 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C31H33N2O4¼ 497.2435, found 497.2425.
Hydrochloride: mp 239–241 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-2,3-dimethoxy-1-naphthamide (8)
Procedure A in an. CH2Cl2, starting from aniline 27 and 2,3-dime-
thoxy-1-naphthoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH 95:5.
Yield: 24.1%.
1H NMR (400MHz, CDCl3) d: 7.98 (d, J¼ 8.0 Hz, 1H, CH arom.);
7.90 (s, 1H, NH), 7.67 (d, J¼ 8.0 Hz, 1H, CH arom.); 7.61 (d,
J¼ 8.4 Hz, 2H, CH arom.); 7.42–7.33 (m, 2H, CH arom.); 7.24 (d,
J¼ 8.4 Hz, 2H, CH arom.); 7.10 (s, 1H, CH arom.); 6.57 (s, 1H, CH
arom.); 6.51 (s, 1H, CH arom.); 3.93 (s, 3H, OCH3); 3.88 (s, 3H,
OCH3); 3.82 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.66 (s, 2H, NCH2Ar);
2.95–2.88 (m, 2H, CH2); 2.87–2.74 (m, 6H, CH2) ppm.
13C NMR
(100MHz, CDCl3) d: 164.75 (C¼O); 151.32 (C); 147.63 (C); 147.30
(C); 146.22 (C); 136.57 (C); 136.27 (C); 131.39 (C); 129.38 (CH
arom.); 127.22 (C); 126.73 (CH arom.); 126.03 (C); 125.96 (CH
arom.); 125.12 (CH arom.); 124.71 (CH arom.); 120.17 (CH arom.);
111.37 (CH arom.); 109.49 (CH arom.); 108.85 (CH arom.); 62.40
(OCH3); 60.01 (CH2); 55.95 (OCH3); 55.91 (OCH3); 55.76 (OCH3);
55.55 (CH2); 50.97 (CH2); 33.32 (CH2); 28.47 (CH2) ppm. ESI-HRMS
(m/z) calculated for [MþH]þ ion species C32H35N2O5¼ 527.2541,
found 527.2534.
Hydrochloride: mp 245–248 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phe-
nyl)nicotinamide (9)
Procedure B in an. CH3CN, starting from aniline 27 and nico-
tinic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 40.5%.
1H NMR (400MHz, CDCl3) d: 9.02 (s, 1H, NH); 8.70 (s, 1H, CH
arom.); 8.62 (d, J¼ 4.4 Hz, 1H, CH arom.); 8.13 (d, J¼ 8.0 Hz, 1H,
CH arom.); 7.52 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.30 (dd, J¼ 8.0,
4.4 Hz, 1H, CH arom.); 7.16 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.54 (s,
1H, CH arom.); 6.48 (s, 1H, CH arom.); 3.77 (s, 3H, OCH3); 3.76 (s,
3H, OCH3); 3.60 (s, 2H, NCH2Ar); 2.87–2.67 (m, 8H, CH2) ppm.
13C
NMR (100MHz, CDCl3) d: 164.18 (C¼O); 152.07 (CH arom.); 148.30
(CH arom.); 147.52 (C); 147.19 (C); 136.87 (C); 135.95 (C); 135.48
(CH arom.); 130.80 (C); 129.21 (CH arom.); 126.26 (C); 126.04 (C);
123.49 (CH arom.); 120.97 (CH arom.); 111.36 (CH arom.); 109.48
(CH arom.); 59.96 (CH2); 55.88 (OCH3); 55.84 (OCH3); 55.57 (CH2);
50.96 (CH2); 33.30 (CH2); 28.53 (CH2) ppm. ESI-HRMS (m/z) calcu-
lated for [MþH]þ ion species C25H28N3O3¼ 418.2125,
found 418.2128.
Hydrochloride: mp 151–154 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-6-methoxynicotinamide (10)
Procedure B in an. CH3CN, starting from aniline 27 and 6-methox-
ynicotinic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 29.3%.
1H NMR (400MHz, CDCl3) d: 8.65 (s, 1H, CH arom.); 8.03 (d,
J¼ 8.4 Hz, 1H, CH arom.); 7.89 (s, 1H, NH); 7.50 (d, J¼ 6.8 Hz, 2H,
CH arom.); 7.18 (d, J¼ 6.8 Hz, 2H, CH arom.); 6.75 (d, J¼ 8.4 Hz, 1H,
CH arom.); 6.56 (s, 1H, CH arom.); 6.50 (s, 1H, CH arom.); 3.95 (s,
3H, OCH3); 3.80 (s, 3H, OCH3); 3.79 (s, 3H, OCH3); 3.63 (s, 2H,
NCH2Ar); 2.91–2.70 (m, 8H, CH2) ppm.
13C NMR (100MHz, CDCl3)
d: 166.07 (C¼O); 164.08 (C); 147.67 (C); 147.33 (C); 146.84 (CH
arom.); 137.93 (CH arom.); 136.31 (C); 136.15 (C); 129.20 (CH
arom.); 125.83 (C); 124.04 (C); 120.79 (CH arom.); 111.38 (CH
arom.); 110.78 (CH arom.); 109.50 (CH arom.); 59.69 (CH2); 55.92
(OCH3); 55.89 (OCH3); 55.34 (CH2); 53.94 (OCH3); 50.82 (CH2); 33.08
(CH2); 28.25 (CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion
species C26H30N3O4¼ 448.2231, found 448.2236.
Hydrochloride: mp 123–126 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phe-
nyl)pyrazine-2-carboxamide (11)
Procedure A in an. CH2Cl2, starting from aniline 27 and pyrazine-
2-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 63.8%.
1H NMR (400MHz, CDCl3) d: 9.59 (s, 1H, NH); 9.45 (d, J¼ 1.2 Hz,
1H, CH arom.); 8.73 (d, J¼ 2.4 Hz, 1H, CH arom.); 8.51 (dd, J¼ 2.4,
1.2 Hz, 1H, CH arom.); 7.64 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.22 (d,
J¼ 8.4 Hz, 2H, CH arom.); 6.55 (s, 1H, CH arom.); 6.48 (s, 1H, CH
arom.); 3.79 (s, 3H, OCH3); 3.78 (s, 3H, OCH3); 3.61 (s, 2H, NCH2Ar);
2.90–2.83 (m, 2H, CH2); 2.82–2.69 (m, 6H, CH2) ppm.
13C NMR
(100MHz, CDCl3) d: 160.55 (C¼O); 147.60 (C); 147.47 (CH arom.);
147.28 (C); 144.62 (CH arom.); 144.44 (C); 142.35 (CH arom.);
136.95 (C); 135.35 (C); 129.40 (CH arom.); 126.32 (C); 126.07 (C);
119.96 (CH arom.); 111.42 (CH arom.); 109.53 (CH arom.); 59.98
(CH2); 55.94 (OCH3); 55.90 (OCH3); 55.62 (CH2); 50.99 (CH2); 33.41
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(CH2); 28.57 (CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion
species C24H27N4O3¼ 419.2078, found 419.2079.
Hydrochloride: mp 246–249 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-6-methoxypyrazine-2-carboxamide (12)
Procedure B in an. CH3CN, starting from aniline 27 and 6-methox-
ypyrazine-2-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 89.5%.
1H NMR (400MHz, CDCl3) d: 9.32 (s, 1H, NH); 9.02 (s, 1H, CH
arom.); 8.41 (s, 1H, CH arom.); 7.62 (d, J¼ 8.4 Hz, 2H, CH arom.);
7.24 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.57 (s, 1H, CH arom.); 6.50 (s,
1H, CH arom.); 4.06 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.80 (s, 3H,
OCH3); 3.65 (s, 2H, NCH2Ar); 2.95–2.87 (m, 2H, CH2); 2.86–2.73 (m,
6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 160.76 (C¼O); 140.43
(C); 139.35 (CH arom.); 138.65 (C); 136.53 (C); 136.14 (CH arom.);
135.37 (C); 132.67 (C); 132.13 (C); 129.45 (CH arom.); 125.67 (C);
125.45 (C); 120.13 (CH arom.); 111.31 (CH arom.); 109.42 (CH
arom.); 59.58 (CH2); 55.95 (OCH3); 55.91 (OCH3); 55.29 (CH2); 53.89
(OCH3); 50.82 (CH2); 33.10 (CH2); 28.04 (CH2) ppm. ESI-HRMS (m/z)
calculated for [MþH]þ ion species C25H29N4O4¼ 449.2183,
found 449.2187.
Hydrochloride: mp 224–226 C.
N-(4–(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-
phenyl)-6-methoxyquinoline-4-carboxamide (13)
Procedure B in CHCl3 (free of ethanol), starting from aniline 27
and 6-methoxyquinoline-4-carboxylic acid.
Free base: yield: 100.0%.
1H NMR (400MHz, CDCl3) d: 9.24 (s, 1H, NH); 8.35 (d, J¼ 4.0 Hz,
1H, CH arom.); 7.78 (d, J¼ 9.2 Hz, 1H, CH arom.); 7.68 (d, J¼ 8.0 Hz,
2H, CH arom.); 7.30 (d, J¼ 2.0 Hz, 1H, CH arom.); 7.24–7.20 (m, 3H,
CH arom.); 7.13 (d, J¼ 4.0 Hz, 1H, CH arom.); 6.55 (s, 1H, CH
arom.); 6.49 (s, 1H, CH arom.); 3.78 (s, 6H, OCH3); 3.76 (s, 3H,
OCH3); 3.63 (s, 2H, NCH2Ar); 2.93–2.87 (m, 2H, CH2); 2.85–2.73 (m,
6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 165.86 (C¼O); 158.41
(C); 147.50 (C); 147.16 (C); 146.62 (CH arom.); 144.34 (C); 140.14
(C); 136.87 (C); 136.27 (C); 130.51 (CH arom.); 129.32 (CH arom.);
126.09 (C); 125.95 (C); 125.45 (C); 122.94 (CH arom.); 120.57 (CH
arom.); 118.92 (CH arom.); 111.31 (CH arom.); 109.43 (CH arom.);
102.57 (CH arom.); 59.92 (CH2); 55.87 (OCH3); 55.83 (OCH3); 55.52
(OCH3); 55.48 (CH2); 50.88 (CH2); 33.21 (CH2); 28.42 (CH2) ppm. ESI-
HRMS (m/z) calculated for [MþH]þ ion species C30H32N3O4¼
498.2387, found 498.2395.
Hydrochloride: mp 228–230 C.
General procedures for the synthesis of the ester
compounds 14–26
Compounds were synthesised using two different gen-
eral procedures.
General procedure A. To a solution of the phenol 2834
(0.25mmol) in 5ml of an. CH2Cl2 or an. CH3CN at 0 C, the proper
carboxylic acid (0.30mmol), DMAP (0.20mmol) and EDC hydro-
chloride (0.45mmol) were added. The reaction mixture was stirred
at 0 C for 1 h then at room temperature for 48 h. The mixture
was treated with CH2Cl2 and the organic layer was washed with
water and with a saturated solution of NaHCO3. After drying with
Na2SO4, the solvent was removed under reduced pressure. The
residue was then purified by flash chromatography using the
appropriate eluting system, obtaining the desired compound as
an oil.
General procedure B. The proper carboxylic acid (0.30mmol)
was transformed into the acyl chloride by reaction with SOCl2 (4
eq) in 5ml of CHCl3 (free of ethanol) or an. CH3CN at 60 C for
6–8 h. The reaction mixture was cooled to rt, and the solvent was
removed under reduced pressure. The mixture was then treated
twice with cyclohexane and the solvent removed under reduce
pressure. The acyl chloride obtained was dissolved in CHCl3 (free
of ethanol), and the phenol 2834 (0.25mmol) was added. The mix-
ture was kept at rt for 24 h, then the organic layer was washed
twice with a saturated solution of NaHCO3. After drying with
Na2SO4, the solvent was removed under reduced pressure. The
residue obtained was purified by flash chromatography using the
appropriate eluting system, yielding the desired compound as
an oil.
In both procedures A and B, all the compounds were trans-
formed into the corresponding hydrochloride as solid. The salts
were crystallised from abs. ethanol/petroleum ether.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2,3,4-trimethoxybenzoate (14)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and 2,3,4-trimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 17.2%.
1H NMR (400MHz, CDCl3) d: 7.79 (d, J¼ 8.8 Hz, 1H, CH arom.);
7.28 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.13 (d, J¼ 8.4 Hz, 2H, CH arom.);
6.75 (d, J¼ 8.8 Hz, 1H, CH arom.); 6.60 (s, 1H, CH arom.); 6.53 (s,
1H, CH arom.); 3.97 (s, 3H, OCH3); 3.93 (s, 3H, OCH3); 3.89 (s, 3H,
OCH3); 3.84 (s, 3H, OCH3); 3.83 (s, 3H, OCH3); 3.68 (s, 2H, NCH2Ar);
2.97–2.91 (m, 2H, CH2); 2.90–2.76 (m, 6H, CH2) ppm.
13C NMR
(100MHz, CDCl3) d: 163.97 (C¼O); 157.79 (C); 155.34 (C); 149.32
(C); 147.66 (C); 147.33 (C); 143.19 (C); 137.61 (C); 129.67 (CH
arom.); 127.50 (CH arom.); 126.03 (C); 125.94 (C); 121.76 (CH
arom.); 117.10 (C); 111.39 (CH arom.); 109.51 (CH arom.); 107.03
(CH arom.); 61.90 (OCH3); 61.06 (OCH3); 59.88 (CH2); 56.15 (OCH3);
55.95 (OCH3); 55.91 (OCH3); 55.50 (CH2); 50.96 (CH2); 33.25 (CH2);
28.40 (CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion spe-
cies C29H34NO7¼ 508.2330, found 508.2326.
Hydrochloride: mp 207–210 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2-methoxybenzoate (15)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and 2-methoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 44.6%.
1H NMR (400MHz, CDCl3) d: 7.95 (dd, J¼ 8.0, 1.8 Hz, 1H, CH
arom.); 7.48 (td, J¼ 8.0, 1.8 Hz, 1H, CH arom.); 7.23 (d, J¼ 8.4 Hz,
2H, CH arom.); 7.11 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.02–6.96 (m, 2H,
CH arom.); 6.56 (s, 1H, CH arom.); 6.50 (s, 1H, CH arom.); 3.87 (s,
3H, OCH3); 3.79 (s, 3H, OCH3); 3.78 (s, 3H, OCH3); 3.61 (s, 2H,
NCH2Ar); 2.93–2.85 (m, 2H, CH2); 2.84–2.70 (m, 6H, CH2) ppm.
13C
NMR (100MHz, CDCl3) d: 164.53 (C¼O); 159.79 (C); 149.31 (C);
147.62 (C); 147.30 (C); 137.70 (C); 134.22 (CH arom.); 132.09 (CH
arom.); 129.59 (CH arom.); 126.31 (C); 126.07 (C); 121.72 (CH
arom.); 120.21 (CH arom.); 119.28 (C); 112.27 (CH arom.); 111.46
(CH arom.); 109.58 (CH arom.); 59.97 (CH2); 56.05 (OCH3); 55.95
(OCH3); 55.92 (OCH3); 55.59 (CH2); 51.00 (CH2); 33.34 (CH2); 28.55
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 979
(CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C27H30NO5¼ 448.2119, found 448.2123.
Hydrochloride: mp 220–222 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2,4-dimethoxybenzoate (16)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and 2,4-dimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 18.7%.
1H NMR (400MHz, CDCl3) d: 8.02 (d, J¼ 8.8 Hz, 1H, CH arom.);
7.23 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.09 (d, J¼ 8.4 Hz, 2H, CH arom.);
6.57 (s, 1H, CH arom.); 6.52 (dd, J¼ 8.8, 2.2 Hz, 1H, CH arom.); 6.51
(s, 1H, CH arom.); 6.49 (d, J¼ 2.2 Hz, 1H, CH arom.); 3.87 (s, 3H,
OCH3); 3.85 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.80 (s, 3H, OCH3);
3.66 (s, 2H, NCH2Ar); 2.96–2.89 (m, 2H, CH2); 2.88–2.74 (m, 6H,
CH2) ppm.
13C NMR (100MHz, CDCl3) d: 164.90 (C¼O); 163.83 (C);
162.15 (C); 149.52 (C); 147.80 (C); 147.44 (C); 136.84 (C); 134.43 (CH
arom.); 129.55 (CH arom.); 125.51 (C); 121.97 (CH arom.); 111.33
(CH arom.); 109.44 (CH arom.); 104.79 (CH arom.); 99.04 (CH
arom.); 59.45 (CH2); 56.03 (OCH3); 55.96 (OCH3); 55.92 (OCH3);
55.57 (OCH3); 55.11 (CH2); 50.77 (CH2); 32.91 (CH2); 27.87 (CH2)
ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C28H32NO6¼ 478.2224, found 478.2230.
Hydrochloride: mp 221–223 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2,6-dimethoxybenzoate (17)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and 2,6-dimethoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 37.4%.
1H NMR (400MHz, CDCl3) d: 7.29 (t, J¼ 8.4 Hz, 1H, CH arom.);
7.24 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.14 (d, J¼ 8.4 Hz, 2H, CH arom.);
6.56 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.56 (s, 1H, CH arom.); 6.50 (s,
1H, CH arom.); 3.83 (s, 6H, OCH3); 3.80 (s, 3H, OCH3); 3.79 (s, 3H,
OCH3); 3.65 (s, 2H, NCH2Ar); 2.94–2.87 (m, 2H, CH2); 2.86–2.70 (m,
6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 165.12 (C¼O); 157.63
(C); 149.47 (C); 147.71 (C); 147.37 (C); 137.59 (C); 131.58 (CH
arom.); 129.62 (CH arom.); 125.87 (C); 121.75 (CH arom.); 112.52
(C); 111.42 (CH arom.); 109.55 (CH arom.); 104.04 (CH arom.); 59.73
(CH2); 56.13 (OCH3); 55.96 (OCH3); 55.92 (OCH3); 55.39 (CH2); 50.90
(CH2); 33.19 (CH2); 28.28 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C28H32NO6¼ 478.2224, found 478.2224.
Hydrochloride: mp 213–215 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2,3-dimethoxybenzoate (18)
Procedure A in an. CH2Cl2, starting from phenol 28 and 2,3-dime-
thoxybenzoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 65.5%.
1H NMR (400MHz, CDCl3) d: 7.47 (dd, J¼ 7.2, 2.2 Hz, 1H, CH
arom.); 7.26 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.15–7.07 (m, 4H, CH
arom.); 6.57 (s, 1H, CH arom.); 6.51 (s, 1H, CH arom.); 3.92 (s, 3H,
OCH3); 3.87 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.80 (s, 3H, OCH3);
3.66 (s, 2H, NCH2Ar); 2.96–2.89 (m, 2H, CH2); 2.88–2.68 (m, 6H,
CH2) ppm.
13C NMR (100MHz, CDCl3) d: 164.74 (C¼O); 153.76 (C);
149.71 (C); 149.27 (C); 147.66 (C); 147.33 (C); 137.78 (C); 129.72 (CH
arom.); 125.93 (C); 125.43 (C); 123.95 (CH arom.); 122.54 (CH
arom.); 121.68 (CH arom.); 116.44 (CH arom.); 111.38 (CH arom.);
109.50 (CH arom.); 61.60 (OCH3); 59.88 (CH2); 56.14 (OCH3); 55.95
(OCH3); 55.92 (OCH3); 55.51 (CH2); 50.97 (CH2); 33.27 (CH2); 28.42
(CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C28H32NO6¼ 478.2224, found 478.2221.
Hydrochloride: mp 237–239 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
1-naphthoate (19)
Procedure A in an. CH2Cl2, starting from phenol 28 and 1-naph-
thoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 77.5%.
1H NMR (400MHz, CDCl3) d: 9.00 (d, J¼ 8.0 Hz, 1H, CH arom.);
8.44 (d, J¼ 7.6 Hz, 1H, CH arom.); 8.07 (d, J¼ 8.0 Hz, 1H, CH arom.);
7.89 (d, J¼ 7.6 Hz, 1H, CH arom.); 7.61 (t, J¼ 7.6 Hz, 1H, CH arom.);
7.54 (t, J¼ 8.0 Hz, 2H, CH arom.); 7.31 (d, J¼ 8.4 Hz, 2H, CH arom.);
7.19 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.59 (s, 1H, CH arom.); 6.53 (s,
1H, CH arom.); 3.82 (s, 6H, OCH3); 3.67 (s, 2H, NCH2Ar); 2.99–2.91
(m, 2H, CH2); 2.90–2.76 (m, 6H, CH2) ppm.
13C NMR (100MHz,
CDCl3) d: 165.97 (C¼O); 149.32 (C); 147.67 (C); 147.35 (C); 137.93
(C); 134.30 (CH arom.); 133.95 (C); 131.70 (C); 131.19 (CH arom.);
129.82 (CH arom.); 128.71 (CH arom.); 128.17 (CH arom.); 126.42
(CH arom.); 126.14 (C); 126.00 (C); 125.76 (CH arom.); 124.54 (CH
arom.); 121.81 (CH arom.); 111.42 (CH arom.); 109.54 (CH arom.);
59.94 (CH2); 55.97 (OCH3); 55.94 (OCH3); 55.59 (CH2); 51.01 (CH2);
33.35 (CH2); 28.50 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C30H30NO4¼ 468.2169, found 468.2174.
Hydrochloride: mp 227–230 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2-methoxy-1-naphthoate (20)
Procedure A in an CH2Cl2, starting from phenol 28 and 2-
methoxy-1-naphthoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
95:5:0.5. Yield: 73.3%.
1H NMR (400MHz, CDCl3) d: 7.92 (d, J¼ 8.8 Hz, 2H, CH arom);
7.80 (d, J¼ 7.6 Hz, 1H, CH arom.); 7.52 (t, J¼ 7.6 Hz, 1H, CH arom.);
7.38 (t, J¼ 7.6 Hz, 1H, CH arom.); 7.34–7.27 (m, 3H, CH arom.); 7.25
(d, J¼ 8.4 Hz, 2H, CH arom.); 6.58 (s, 1H, CH arom.); 6.52 (s, 1H, CH
arom.); 4.00 (s, 3H, OCH3); 3.83 (s, 3H, OCH3); 3.82 (s, 3H, OCH3);
3.65 (s, 2H, NCH2Ar); 3.00–2.90 (m, 2H, CH2); 2.89–2.75 (m, 6H,
CH2) ppm.
13C NMR (100MHz, CDCl3) d: 166.67 (C¼O); 155.02 (C);
149.38 (C); 147.67 (C); 147.34 (C); 137.85 (C); 132.26 (CH arom.);
131.02 (C); 129.79 (CH arom.); 128.55 (C); 128.24 (CH arom.);
127.92 (CH arom.); 125.86 (C); 124.29 (CH arom.); 123.58 (CH
arom.); 121.71 (CH arom.); 116.70 (C); 113.17 (CH arom.); 111.36
(CH arom.); 109.49 (CH arom.); 59.78 (CH2); 56.92 (OCH3); 55.95
(OCH3); 55.92 (OCH3); 55.43 (CH2); 50.92 (CH2); 33.24 (CH2); 28.32
(CH2) ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C31H32NO5¼ 498.2275, found 498.2272.
Hydrochloride: mp 208–210 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
2,3-dimethoxy-1-naphthoate (21)
Procedure A in an. CH2Cl2, starting from phenol 28 and 2,3-dime-
thoxy-1-naphthoic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
95:5:0.5. Yield: 26.5%.
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1H NMR (400MHz, CDCl3) d: 7.89–7.83 (m 1H, CH arom.);
7.75–7.69 (m, 1H, CH arom.); 7.44–7.38 (m, 2H, CH arom.); 7.32 (d,
J¼ 8.0 Hz, 2H, CH arom.); 7.26 (s, 1H, CH arom.); 7.25 (d, J¼ 8.0 Hz,
2H, CH arom.); 6.58 (s, 1H, CH arom.); 6.52 (s, 1H, CH arom.); 4.02
(s, 3H, OCH3); 3.98 (s, 3H, OCH3); 3.82 (s, 3H, OCH3); 3.81 (s, 3H,
OCH3); 3.65 (s, 2H, NCH2Ar); 2.98–2.90 (m, 2H, CH2); 2.89–2.74 (m,
6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d: 166.08 (C¼O); 151.66
(C); 149.22 (C); 147.66 (C); 147.48 (C); 147.33 (C); 138.08 (C); 131.14
(C); 129.90 (CH arom.); 126.90 (CH arom.); 125.90 (CH arom.);
125.47 (C); 125.31 (CH arom.); 123.95 (CH arom.); 123.59 (C);
121.66 (CH arom.); 111.36 (CH arom.); 109.61 (CH arom.); 109.48
(CH arom.); 61.94 (OCH3); 59.85 (CH2); 55.95 (OCH3); 55.91 (OCH3);
55.87 (OCH3); 55.49 (CH2); 50.95 (CH2); 33.27 (CH2); 28.39 (CH2)
ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C32H34NO6¼ 528.2381, found 528.2384.
Hydrochloride: mp 183–185 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
nicotinate (22)
Procedure A in an. CH3CN, starting from phenol 28 and nico-
tinic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 16.7%.
1H NMR (400MHz, CDCl3) d: 9.36 (s, 1H, CH arom.); 8.82 (d,
J¼ 4.8, 1H, CH arom.); 8.41 (d, J¼ 8.0, 1H, CH arom.); 7.43 (dd,
J¼ 8.0, 4.8 Hz, 1H, CH arom.); 7.28 (d, J¼ 8.4 Hz, 2H, CH arom.);
7.12 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.57 (s, 1H, CH arom.); 6.51 (s,
1H, CH arom.); 3.81 (s, 3H, OCH3); 3.80 (s, 3H, OCH3); 3.65 (s, 2H,
NCH2Ar); 2.97–2.90 (m, 2H, CH2); 2.88–2.74 (m, 6H, CH2) ppm.
13C
NMR (100MHz, CDCl3) d: 164.00 (C¼O); 153.97 (CH arom.); 151.37
(CH arom.); 148.87 (C); 147.73 (C); 147.39 (C); 138.14 (C); 137.57
(CH arom.); 129.85 (CH arom.); 125.84 (C); 125.65 (C); 123.45 (CH
arom.); 121.46 (CH arom.); 111.40 (CH arom.); 109.52 (CH arom.);
59.64 (CH2); 55.96 (OCH3); 55.92 (OCH3); 55.40 (CH2); 50.88 (CH2);
33.16 (CH2); 28.26 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C25H27N2O4¼ 419.1965, found 419.1958.
Hydrochloride: mp 98–100 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
6-methoxynicotinate (23)
Procedure B in an. CH3CN, starting from phenol 28 and 6-methox-
ynicotinic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
95:5:0.5. Yield: 21.0%.
1H NMR (400MHz, CDCl3) d: 8.97 (d, J¼ 2.0 Hz, 1H, CH arom.);
8.25 (dd, J¼ 8.8, 2.0 Hz, 1H, CH arom.); 7.27 (d, J¼ 8.4 Hz, 2H, CH
arom.); 7.10 (d, J¼ 8.4 Hz, 2H, CH arom.); 6.80 (d, J¼ 8.8 Hz, 1H, CH
arom.); 6.58 (s, 1H, CH arom.); 6.51 (s, 1H, CH arom.); 4.00 (s, 3H,
OCH3); 3.82 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.69 (s, 2H, NCH2Ar);
3.00–2.92 (m, 2H, CH2); 2.91–2.77 (m, 6H, CH2) ppm. ESI-HRMS (m/
z) calculated for [MþH]þ ion species C26H29N2O5¼ 449.2071,
found 449.2063.
Hydrochloride: mp 254–256 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
pyrazine-2-carboxylate (24)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and pyrazine-2-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 21.8%.
1H NMR (400MHz, CDCl3) d: 9.40 (d, J¼ 1.2 Hz, 1H, CH arom.);
8.78 (d, J¼ 2.4 Hz, 1H, CH arom.); 8.75 (dd, J¼ 2.4, 1.2 Hz, 1H, CH
arom.); 7.26 (d, J¼ 8.8 Hz, 2H, CH arom.); 7.14 (d, J¼ 8.8 Hz, 2H, CH
arom.); 6.55 (s, 1H, CH arom.); 6.49 (s, 1H, CH arom.); 3.79 (s, 3H,
OCH3); 3.78 (s, 3H, OCH3); 3.61 (s, 2H, NCH2Ar); 2.92–2.85 (m, 2H,
CH2); 2.83–2.72 (m, 6H, CH2) ppm.
13C NMR (100MHz, CDCl3) d:
162.66 (C¼O); 148.80 (C); 148.16 (CH arom.); 147.71 (C); 147.36 (C);
146.77 (CH arom.); 144.67 (CH arom.); 142.96 (C); 138.18 (C);
129.93 (CH arom.); 125.62 (C); 125.36 (C); 121.40 (CH arom.);
111.29 (CH arom.); 109.40 (CH arom.); 59.38 (CH2); 55.93 (OCH3);
55.89 (OCH3); 55.17 (CH2); 50.73 (CH2); 32.97 (CH2); 27.97 (CH2)
ppm. ESI-HRMS (m/z) calculated for [MþH]þ ion species
C24H26N3O4¼ 420.1918, found 420.1911.
Hydrochloride: mp 96–99 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
6-methoxypyrazine-2-carboxylate (25)
Procedure B in an. CH3CN, starting from phenol 28 and 6-methox-
ypyrazine-2-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
93:7:0.3. Yield: 75.6%.
1H NMR (400MHz, CDCl3) d: 8.95 (s, 1H, CH arom.); 8.41 (s, 1H,
CH arom.); 7.28 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.14 (d, J¼ 8.4 Hz, 2H,
CH arom.); 6.57 (s, 1H, CH arom.); 6.50 (s, 1H, CH arom.); 4.05 (s,
3H, OCH3); 3.81 (s, 3H, OCH3); 3.80 (s, 3H, OCH3); 3.63 (s, 2H,
NCH2Ar); 2.95–2.90 (m, 2H, CH2); 2.89–2.73 (m, 6H, CH2) ppm.
13C
NMR (100MHz, CDCl3) d: 162.79 (C¼O); 159.99 (C); 148.90 (C);
147.62 (C); 147.29 (C); 140.08 (CH arom.); 139.08 (C); 138.38 (CH
arom.); 138.33 (C); 129.82 (CH arom.); 126.09 (C); 125.96 (C); 121.34
(CH arom.); 111.37 (CH arom.); 109.49 (CH arom.); 59.80 (CH2);
55.93 (OCH3); 55.90 (OCH3); 55.52 (CH2); 54.13 (OCH3); 50.94 (CH2);
33.27 (CH2); 28.44 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C25H28N3O5¼ 450.2024, found 450.2029.
Hydrochloride: mp 214–216 C.
4–(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl
6-methoxyquinoline-4-carboxylate (26)
Procedure B in CHCl3 (free of ethanol), starting from phenol 28
and 6-methoxyquinoline-4-carboxylic acid.
Free base: chromatographic eluent: CH2Cl2/MeOH/NH4OH
97:3:0.3. Yield: 32.5%.
1H NMR (400MHz, CDCl3) d: 8.93 (d, J¼ 4.8 Hz, 1H, CH arom.);
8.33 (d, J¼ 2.4 Hz, 1H, CH arom.); 8.19 (d, J¼ 4.8 Hz, 1H, CH arom.);
8.09 (d, J¼ 9.2 Hz, 1H, CH arom.); 7.44 (dd, J¼ 9.2, 2.4 Hz, 1H, CH
arom.); 7.36 (d, J¼ 8.4 Hz, 2H, CH arom.); 7.20 (d, J¼ 8.4 Hz, 2H, CH
arom.); 6.61 (s, 1H, CH arom.); 6.55 (s, 1H, CH arom.); 3.93 (s, 3H,
OCH3); 3.85 (s, 3H, OCH3); 3.84 (s, 3H, OCH3); 3.71 (s, 2H, NCH2Ar);
3.02–2.97 (m, 2H, CH2); 2.92–2.80 (m, 6H, CH2) ppm.
13C NMR
(100MHz, CDCl3) d: 165.03 (C¼O); 159.57 (C); 148.91 (C); 147.79
(C); 147.42 (C); 146.93 (CH arom.); 145.80 (C); 137.98 (C); 131.57
(CH arom.); 131.20 (C); 130.04 (CH arom.); 127.04 (C); 125.50 (C);
123.37 (CH arom.); 123.15 (CH arom.); 121.68 (CH arom.); 111.26
(CH arom.); 109.37 (CH arom.); 102.97 (CH arom.); 59.36 (CH2);
55.95 (OCH3); 55.91 (OCH3); 55.65 (OCH3); 55.12 (CH2); 50.74 (CH2);
32.91 (CH2); 27.90 (CH2) ppm. ESI-HRMS (m/z) calculated for
[MþH]þ ion species C30H31N2O5¼ 499.2228, found 499.2226.
Hydrochloride: mp 203–206 C.
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2-Methoxy-1-naphthoic acid (29)42
To a stirred solution of CuBr2 (0.04mmol) and 2-methoxy-1-naph-
thaldehyde (0.80mmol) in 3.0ml of an CH3CN was added 70% t-
BuOOH in water (1.60mmol). When all the aldehyde had been
consumed, the solvent was removed under reduced pressure. The
reaction mixture was treated with a saturated solution of NaHCO3
and extracted with ethyl acetate. The aqueous layer was acidified
using 2M HCl and then extracted with ethyl acetate. The organic
phase was dried with Na2SO4, then the solvent was removed
under reduced pressure. 2-methoxy-1-naphthoic acid was
obtained pure as a pale yellow solid.
Yield: 67.6%. 1H NMR (400MHz, CDCl3) d: 8.38 (d, J¼ 8.4 Hz, 1H,
CH arom.); 7.95 (d, J¼ 9.2 Hz, 1H, CH arom.); 7.78 (d, J¼ 8.4 Hz, 1H,
CH arom.); 7.55 (t, J¼ 8.4 Hz, 1H, CH arom.); 7.39 (t, J¼ 8.4 Hz, 1H,
CH arom.); 7.30 (d, J¼ 9.2 Hz, 1H, CH arom.); 4.05 (s, 3H, OCH3).
2,3-Dimethoxy-1-naphthoic acid (30)43
To a solution of 2,3-dimethoxy-1-naphthaldehyde (0.23mmol) in
3.0ml of acetone was added Na2CO3 (0.23mmol) in 1.0ml of
water. Then KMnO4 (0.23mmol) was added portion wise. The reac-
tion mixture was stirred at rt for 18 h then filtered. The filtrate was
concentrated and extracted with ethyl acetate. The aqueous layer
was acidified to pH 1 with 1M HCl then extracted with ethyl acet-
ate. After drying with Na2SO4, the solvent was removed under
reduced pressure and 2,3-dimethoxy-1-naphthoic acid was
obtained as a pale yellow solid.
Yield: 93.3%. 1H NMR (400MHz, CDCl3) d: 10.40 (s, 1H, OH);
7.89 (d, J¼ 7.6 Hz, 1H, CH arom.); 7.63 (d, J¼ 7.6 Hz, 1H, CH arom.);
7.35 (t, J¼ 7.6 Hz, 1H, CH arom.); 7.30 (t, J¼ 7.6 Hz, 1H, CH arom.);
7.14 (s, 1H, CH arom.); 3.92 (s, 3H, OCH3); 3.89 (s, 3H, OCH3).
6-Methoxyquinoline-4-carboxylic acid (31)44
To a solution of quinine sulphate (0.90mmol) in 12ml of 10% sul-
phuric acid, MnO2 (1.70mmol) was added. The mixture was raised
to the boiling point, then CrO3 (14.30mmol) dissolved in 3ml of
water was added dropwise during an hour. The refluxing was con-
tinued for 3 h, then 126ml of water and 28ml of 15N ammonia
were added. The reaction mixture was stirred at 100 C for 18 h,
then filtered with Celite. The residue was washed several times
with hot 15N ammonia solution. The combined filtrates were con-
centrated under reduced pressure, then acidified with acetic acid
and filtered, to obtain 6-methoxyquinoline-4-carboxylic acid as
pure yellow solid.
Yield: 89.4%. 1H NMR (400MHz, DMSO-d6) d: 8.83 (d, J¼ 2.0 Hz,
1H, CH arom.); 8.16 (s, 1H, CH arom.); 7.99 (d, J¼ 9.2 Hz, 1H, CH
arom.); 7.88 (d, J¼ 2.0 Hz, 1H, CH arom.); 7.46 (d, J¼ 9.2 Hz, 1H, CH
arom.); 3.88 (s, 3H, OCH3).
Biological assays
Cell lines and cultures
MDCK-MDR1, MDCK-MRP1 and MDCK-BCRP cells are a gift of Prof.
P. Borst, NKI-AVL Institute, Amsterdam, The Netherlands. Caco-2
cells were a gift of Dr. Aldo Cavallini and Dr. Caterina Messa from
the Laboratory of Biochemistry, National Institute for Digestive
Diseases, “S. de Bellis”, Bari (Italy). HT29 and A549 were purchased
from ATCC (Manassas, VA). The doxorubicin-resistant sublines,
HT29/DX and A549/DX cells were generated by stepwise selection
in medium with increasing concentrations of doxorubicin45 and
maintained in culture medium with 100 and 50 nM doxorubicin,
respectively. MDCK and Caco-2 cells were grown in DMEM high
glucose, HT29 and HT29/DX in RPMI-1640, A549 and A549/DX in
HAM-F12 medium, all supplemented with 10% foetal bovine
serum, 2mM glutamine, 100U/mL penicillin, 100 mg/mL strepto-
mycin, in a humidified incubator at 37 C with a 5%
CO2 atmosphere.
Drugs and chemicals
Cell culture reagents were purchased from Celbio s.r.l. (Milano,
Italy). CulturePlate 96/wells plates were purchased from
PerkinElmer Life Science; Calcein-AM, bisBenzimide H 33342 trihy-
drochloride were obtained from Sigma-Aldrich (Milan, Italy).
Immunoblotting analysis of P-gp, MRP1 and BCRP expression in
MDCK, MDCK-MDR1, MDCK-MRP1 and MDCK-BCRP cells
All MDCK cells were rinsed with lysis buffer (50mM Tris-HCl, 1mM
EDTA, 1mM EGTA, 150mM NaCl, 1% v/v Triton-X100; pH 7.4), sup-
plemented with the protease inhibitor cocktail III (Cabiochem, La
Jolla, CA), sonicated and clarified at 13000g, for 10min at 4 C.
Protein extracts (20 mg) were subjected to SDS-PAGE and probed
with the following antibodies: anti-P-glycoprotein (P-gp; 1:250,
rabbit polyclonal, #sc-8313, Santa Cruz Biotechnology Inc., Santa
Cruz, CA), anti-multidrug resistant protein 1 (MRP1; 1:500, mouse
clone MRPm5, Abcam, Cambridge, UK), anti-breast cancer resist-
ance protein (BCRP; 1:500, mouse clone BXP-21, Santa Cruz
Biotechnology Inc.), anti-b-tubulin (1:1000, mouse clone D10,
Santa Cruz Biotechnology Inc.), followed by the horseradish perox-
idase-conjugated secondary antibodies (Bio-Rad). The membranes
were washed with Tris-buffered saline (TBS)/Tween 0.01% v/v.
Proteins were detected by enhanced chemiluminescence (Bio-Rad
Laboratories).
Calcein-AM experiments
These experiments were carried out as previously described by
Teodori et al. with minor modifications34. Each cell line (30 000
cells per well) was seeded into black CulturePlate 96/wells plate
with 100mL medium and allowed to become confluent overnight.
100 mL of test compounds were solubilised in culture medium and
added to monolayers, with final concentrations ranging from 1nM
to 100 mM. 96/Wells plate was incubated for 30min in a humidi-
fied atmosphere 5% CO2 at 37 C. Calcein-AM was added in
100 mL of Phosphate Buffered Saline (PBS) to yield a final concen-
tration of 2.5mM and plate was incubated for 30min in a humidi-
fied atmosphere 5% CO2 at 37 C. Each well was washed 3 times
with ice cold PBS. Saline buffer was added to each well and the
plate was read with Victor3 (PerkinElmer) at excitation and emis-
sion wavelengths of 485 and 535 nm, respectively. In these experi-
mental conditions, Calcein cell accumulation in the absence and
in the presence of tested compounds was evaluated and fluores-
cence basal level was estimated with untreated cells. In treated
wells the increase of fluorescence with respect to basal level was
measured. EC50 values were determined by fitting the fluores-
cence increase percentage versus log[dose].
Hoechst 33342 experiment
These experiments were carried out as described by Teodori
et al.34. Each cell line (30 000 cells per well) was seeded into black
CulturePlate 96/wells plate with 100 mL medium and allowed to
become confluent overnight. 100 mL of test compounds were solu-
bilised in culture medium and added to monolayers, with final
concentrations ranging from 1 to 100 mM. 96/Wells plate was
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incubated for 30min in a humidified atmosphere 5% CO2 at 37 C.
Hoechst 33342 was added in 100 ml of phosphate-buffered saline
(PBS) to yield a final concentration of 8 mM and plate was incu-
bated for 30min in a humidified atmosphere 5% CO2 at 37 C.
The supernatants were drained, and the cells were fixed for
20min under light protection using 100 mL per well of a 4% PFA
solution. Each well was washed three times with ice cold PBS.
Saline buffer was added to each well and the plate was read with
Victor3 (PerkinElmer) at excitation and emission wavelengths of
340/35 nm and 485/20 nm, respectively. In these experimental
conditions, Hoechst 33342 accumulation in the absence and in
the presence of tested compounds was evaluated and fluores-
cence basal level was estimated with untreated cells. In treated
wells, the increase of fluorescence with respect to basal level was
measured. EC50 values were determined by fitting the fluores-
cence increase percentage versus log[dose].
ATPlite assay
The MDCK-MDR1 cells were seeded into 96-well microplate in
100 mL of complete medium at a density 20,000 cells per well. The
plate was incubated overnight (O/N) in a humidified atmosphere
5% CO2 at 37 C. The medium was removed and 100 mL of com-
plete medium either alone or containing different concentrations
(ranging from 1 to 100mM) of test compounds was added. The
plate was incubated for 2 h in a humidified 5% CO2 atmosphere
at 37 C. 50mL of mammalian cell lysis solution was added to all
wells and the plate shacked for five minutes in an orbital shaker.
50mL of substrate solution was added to all wells and the plate
shacked for five minutes in an orbital shaker. The plate was dark
adapted for ten minutes and the luminescence was measured.
Permeability experiments
Preparation of caco-2 monolayer
Caco-2 cells were seeded onto a MillicellVR assay system (Millipore),
where a cell monolayer is set in between a filter cell and a receiver
plate, at a density of 10 000 cells/well46. The culture medium was
replaced every 48 h and the cells kept for 21 days in culture. The
Trans Epithelial Electrical Resistance (TEER) of the monolayers was
measured daily, before and after the experiment, using an epithe-
lial volt-ohmmeter (MillicellVR -ERS). Generally, TEER values greater
than 1000 X for a 21 days culture, are considered optimal.
Drug transport experiment
After 21 days of Caco-2 cell growth, the medium was removed
from filter wells and from the receiver plate, which were filled
with fresh HBSS buffer (Invitrogen). This procedure was repeated
twice, and the plates were incubated at 37 C for 30min. After
incubation time, the HBSS buffer was removed and drug solutions
and reference compounds were added to the filter well at the
concentration of 100 mM, while fresh HBSS was added to the
receiver plate. The plates were incubated at 37 C for 120min.
Afterwards, samples were removed from the apical (filter well) and
basolateral (receiver plate) side of the monolayer to measure the
permeability.
The apparent permeability (Papp), in units of nm/second, was






 VA¼ the volume (in mL) in the acceptor well;
 Area¼ the surface area of the membrane (0.11 cm2 of
the well);
 time¼ the total transport time in seconds (7200s);
 [drug]acceptor¼ the concentration of the drug measured by
U.V. spectroscopy;
 [drug]initial¼ the initial drug concentration (1 104M) in the
apical or basolateral wells.
Co-administration assay
The co-administration assay with doxorubicin was performed in
MDCK-MDR1, HT29, HT29/DX, A549 and A549/DX cells at 48 h.
On day 1, 10,000 cells/well were seeded into 96-well plates in
a volume of 100 mL of fresh medium. On day 2, the tested
drug was added alone to the cells at different concentrations
(ranging from 40 nM to 10mM). On day 3, the medium was
removed and the drug at the same concentrations was added
alone and in co-administration with 10mM doxorubicin to the
cells. After the established incubation time with the tested
drug, MTT (0.5mg/mL) was added to each well, and after
3 4 h incubation at 37 C, the supernatant was removed. The
formazan crystals were solubilised using 100 mL of DMSO/EtOH
(1:1), and the absorbance values at 570 and 630 nm were
determined on the microplate reader HTX Synergy (Bio-Tek
Instruments).
Statistical analysis
All data in the text and figures are provided as means ± SEM. The
results were analysed by a Student’s t-test and one-way ANOVA
test, using Graph-Pad Prism (Graph-Pad software, San Diego, CA).
p< 0.05 was considered significant.
Stability tests
Chemicals
Acetonitrile (Chromasolv), formic acid and ammonium formate
(MS grade), NaCl, KCl, Na2HPO4 2H2O, KH2PO4 (Reagent grade),
verapamil hydrochloride (analytical standard, used as internal
standard) and ketoprofen (analytical standard) were purchased by
Sigma-Aldrich (Milan, Italy). Ketoprofen ethyl ester (KEE) were
obtained by Fisher’s reaction from ketoprofen and ethanol.
MilliQ water 18 MX cm1 was obtained from Millipore’s
Simplicity system (Milan, Italy).
Phosphate-buffered solution was prepared by adding 8.01 g
L1 of NaCl, 0.2 g L1 of KCl, 1.78 g L1 of Na2HPO4 2H2O and
0.27 g L1 of KH2PO4. Human plasma was collected from healthy
male volunteer and kept at 80 C until use.
Preparation of samples
Each sample was prepared adding 10 mL of working solution 1
to 100 mL of tested matrix (PBS or human plasma) in micro
centrifuge tubes. The obtained solutions correspond to 1 mM
of analyte.
Each set of samples was incubated in triplicate at four different
times, 0, 30, 60 and 120min at 37 C. Therefore, the degradation
profile of each analyte was represented by a batch of 12 samples
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(4 incubation times  3 replicates). After the incubation, the sam-
ples were added with 300mL of ISTD solution and centrifuged
(room temperature for 5min at 10,000 rpm). The supernatants
were transferred in auto sampler vials and dried under a gentle
stream of nitrogen.
The dried samples were dissolved in 1.0ml of 10mM of formic
acid in mQ water: acetonitrile 80:20 solution. The obtained sample




The reaction pathways used to synthesise derivatives 1–26 are
reported in Schemes 1–4. The key intermediates needed to
achieve amides and esters were the aniline 27 and the phenol 28,
respectively, which were prepared (Scheme 1) as reported
previously34: aniline 27 was obtained by alkylation of 6,7-dime-
thoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride with 1–(2-
bromoethyl)4-nitrobenzene followed by catalytic reduction of
the nitro group; phenol 28 was synthesised starting from the
commercially available 4-(hydroxyethyl)phenol, transformed in the
corresponding chloroethyl derivative by treatment with SOCl2 in
ethanol-free CHCl3 and anhydrous triethylamine and then reacted
with 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride in
anhydrous CH3CN in the presence of K2CO3. Amides 1–13 and
esters 14–26 were obtained by reaction of 27 and 28, respect-
ively, with the proper carboxylic acid using EDC hydrochloride
and DMAP in anhydrous CH2Cl2 or CH3CN, or with the acyl chlor-
ide obtained by treatment of the suitable acid with SOCl2 in
Scheme 1. Reagents and conditions: (a) 6,7-dimethoxy-1,2,3,4-tetrahydroisoqui-
noline HCl, K2CO3, an. CH3CN; (b) H2, Pd/C, EtOH; (c) SOCl2, ethanol-free CHCl3,
an. Et3N; (d) 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline HCl, K2CO3, an. CH3CN.
Scheme 2. Reagents and conditions: (a) ArCOCl, ethanol-free CHCl3 or an. CH3CN; (b) ArCOOH, EDCI, DMAP, an. CH2Cl2 or CH3CN.
Scheme 3. Reagents and conditions: (a) R¼H, CuBr2, t-BuOOH, an. CH3CN;
R¼OCH3, Na2CO3, KMnO4, acetone.
Scheme 4. Reagents and conditions: (a) H2SO4 (water sol. 10%), MnO2, CrO3,
NH3 (15N).
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ethanol-free CHCl3 or anhydrous CH3CN (Scheme 2, for details see
Experimental Section). Most of the carboxylic acids were commer-
cially available. 2-Methoxy-1-naphthoic acid 29 was synthetised
starting from the corresponding aldehyde, following the general
procedure described by Das42 (Scheme 3), while 2,3-dimethoxy-1-
naphthoic acid 30 was obtained from the corresponding aldehyde
as described by Ohnmacht43 (Scheme 3). 6-Methoxyquinoline-4-
carboxylic acid 31 was synthesised following the procedure
described by Kowanko44 (Scheme 4).
Biological activity: characterisation of P-gp interacting profile
and ABC transporters selectivity
The interaction potency between the designed compounds and
P-gp was evaluated by measuring the transport inhibition of the
pro-fluorescent probe Calcein-AM, that is a P-gp substrate, in a
cell line overexpressing P-gp (MDCK-MDR1)47. The P-gp interacting
profile was further investigated with two other assays: the
Apparent Permeability (Papp) determination (BA/AB) in Caco-2 cell
Table 1. MDR-reversing activity, P-gp interaction profile and calculated human plasma half-life of compounds 1–26.
(EC50) mM
a
Compound X Ar P-gp MRP1 BCRP ATP cell depletion Papp
b t1/2 (min)
c
1 NH a 0.53 ± 0.10 NA 21.2 ± 4.2 No 7.0 240
2 NH b 0.44 ± 0.082 NA 40% No 5.9 240
3 NH c 0.0405 ± 0.008 31%d 1.0 ± 0.2 No 7.4 240
4 NH d 7.20 ± 1.39 NA NA No 5.5 240
5 NH e 0.26 ± 0.050 NA 41%d No 5.0 240
6 NH f 0.67 ± 0.12 NA NA No 3.6 240
7 NH g 0.12 ± 0.022 NA NA No 11.8 240
8 NH h 0.0478 ± 0.0093 47%d NA No 5.5 240
9 NH i 6.40 ± 1.26 NA NA No 7.3 240
10 NH j 2.30 ± 0.44 NA NA No 7.5 240
11 NH k 1.90 ± 0.32 NA NA No 4.9 240
12 NH l 0.87 ± 0.17 NA NA No 6.0 240
13 NH m 0.66 ± 0.13 NA NA No 6.5 240
Ie NH n 1.04 ± 0.20 NA NA No 5.1 240
14 O a 0.36 ± 0.069 69.7 ± 13.9 15.1 ± 2.89 No 9.0 240
15 O b 0.73 ± 0.14 NA 47%d No 5.4 63 ± 14
16 O c 0.10 ± 0.02 87.0 ± 17.0 11.0 ± 2.0 No 7.1 88 ± 22
17 O d 0.15 ± 0.03 NA NA No 6.2 240
18 O e 0.34 ± 0.07 NA 44%d No 4.1 54 ± 9
19 O f 0.84 ± 0.16 NA 35%d No 5.1 240
20 O g 0.11 ± 0.02 NA 7.3 ± 1.4 No 4.8 240
21 O h 0.10 ± 0.02 NA 43%d No 5.4 240
22 O i 29.40 ± 4.98 NA NA No 5.0 240
23 O j 9.24 ± 1.81 NA NA No 5.6 240
24 O k 1.90 ± 0.32 NA NA No 4.9 42 ± 20
25 O l 0.22 ± 0.04 NA NA No 4.7 6 ± 1
26 O m 1.40 ± 0.26 NA NA No 8.7 124 ± 27
IIe O n 0.93 ± 0.18 NA 17.0 ± 3.2 No 5.5 240
tariq 0.044 ± 0.001 ND 0.010 ± 0.005 Yesf >20 ND
elacr 0.014 ± 0.003 NA 10.0 ± 2.0 Yesg >20 ND
aValues are the mean ± SEM of two independent experiments, with samples in triplicate.
bApparent permeability estimation: values are from two independent experiments, with samples in duplicate.
cThe half-life (t1/2) values were referred to the human plasma matrix.
dPercentage of the effect at a concentration of 100 lM.
eSee reference34.
f30% at a concentration of 50 lM.
g25% at a concentration of 10 lM.
NA: not active; ND: not determined.
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monolayer48,49, and the ATP cell depletion in the MDCK-MDR1 cell
line50. Taking into account the results of the combined tests, an
interacting compound can be classified as substrate or inhibitor.
Papp determination measures the ratio between two fluxes: from
the basolateral to apical compartments (BA, representative of pas-
sive diffusion) and from the apical to basolateral compartments
(AB, representative of active transport). A (BA/AB) value <2 sug-
gests that the compound can be considered an inhibitor. In the
same manner, if (BA/AB) >2, the compound should probably be
classified as a substrate51. The other assay detects the consump-
tion of ATP elicited by the transport mediated by the pump; in
general, a substrate induces ATP cell depletion being transported
by the pump (unambiguous substrate, category I), while a P-gp
inhibitor does not induce ATP consumption. There is also a third
substrate category (known as category IIB3) displaying a Papp
value >2 but not inducing an ATP cell depletion47. The selectivity
of ligands 1–26 was evaluated by detecting their activity towards
the other ABC transporters MRP1 and BCRP, by measuring the
inhibition of the efflux of Calcein-AM (i.e., also a MRP1 substrate)
in cells overexpressing MRP1 (MDCK-MRP1 cells), and the inhib-
ition of the efflux of the fluorescent probe Hoechst 33342 (i.e. a
BCRP substrate) in cells overexpressing BCRP (MDCK-BCRP cells),
respectively.
Expression levels of P-gp, MRP1 and BCRP were periodically
analysed by immunoblotting analysis in MDCK-MDR1, MDCK-MRP1
and MDCK-BCRP cells respectively, as described in the
Experimental Section. Tubulin was used as control of equal pro-
tein loading. A representative western blot analysis is reported in
the Supplemental Material.
The results of the three inhibition assays on compounds 1–26
are reported in Table 1 together with those on tariquidar and ela-
cridar used as reference compounds. The already described 3,4,5-
trimethoxyphenyl derivatives I (amide) and II (ester)34 have been
added for comparison.
As shown in Table 1, all the compounds were active on P-gp.
Indeed, most of them showed a high P-gp potency, with EC50 val-
ues below 1mM, reaching also the nanomolar range, as in the
case of compounds 3 and 8 (EC50¼ 40.5 nM and 47.8 nM, respect-
ively). Only eight among the tested derivatives exhibited a lower
P-gp activity, with EC50 values higher than 1 mM.
Our research started with the synthesis of 2,3,4-trimethoxy-
phenyl derivatives 1 (amide) and 14 (ester), which are isomers of
the reference compounds I and II34, reported in Table 1; remark-
ably, both the 2,3,4-functionalized isosteres, bearing a substituent
in ortho position, were more potent than the reference com-































































Figure 3. In vitro cell growth experiments performed on MDCK-MDR1 cells in the presence of 10lM doxorubicin (Doxo) alone and in the presence of different concen-





























































Figure 2. In vitro cell growth experiments performed on MDCK-MDR1 cells in the presence of different concentrations of the two compounds 3 (A) and 8 (B). Each
bar represents the mean± SEM of two experiments performed in triplicate. One-way ANOVA analysis: p< 0.0001.
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analogues carrying an ortho methoxy substituent, also combined
with a second methoxy residue in different positions (amides 2–5
and esters 15–18). Moreover, since in a preceding work we had
verified the positive effect of inserting a naphthalene ring52, we
also obtained compounds 7, 8, 20 and 21 and the non-substi-
tuted analogues 6 and 19 for comparison purposes.
As general trend, substituted benzene and naphthalene deriva-
tives displayed activities in the submicromolar or nanomolar range
(EC50 ranging from 40.5 to 0.67 mM for amides and from 0.10 to
0.84mM for esters), with the exception of amide 4, carrying the
2,6-dimethoxy phenyl moiety, which showed an EC50 value of
7.20mM. In this set of derivatives, it was not easy to define a rela-
tionship between potency values and structural characteristics:
some compounds with interesting EC50 values could be found
both among the amides and the esters, but the nature of the aryl
moieties differently influenced the two groups of isosteres, with-
out a definite trend. However, biological data confirmed that the
presence of an ortho methoxy substituent is favourable for the
activity. The most interesting result was the discovery of two
amides endowed with an outstanding potency in the nanomolar
range: the 2,4-dimethoxy phenyl derivative 3 (EC50 ¼ 0.0405mM)
and the 2,3-dimethoxy naphthalene derivative 8 (EC50
¼ 0.0478 mM).
Compounds 9–13 and 22–26 instead carry a nitrogen-contain-
ing heterocycle: amides 9 and 11, and esters 22 and 24 are non-
substituted pyridine or pyrazine derivatives, while 10, 12, 23 and
25 are the corresponding methoxylated analogues. The quinoline
isosteres 13 and 26 were obtained only as methoxy-substituted
molecules. These hetero aromatic derivatives displayed lower
potency: only amides 12 and 13, and ester 25 showed a moder-
ate/good activity (EC50 ¼ 0.87, 0.66 and 0.22 mM, respectively). In
the case of heterocycles, it was possible to verify that the pres-
ence of the OCH3 substituent improved the inhibiting activity on
P-gp (compare amides 9 with 10, or 11 with 12, and the corre-
sponding esters 22 with 23, or 24 with 25), and that the presence
of an unsubstituted pyridine ring was detrimental for the activity.
As regards the methoxy-quinoline derivatives, amide 13 was more
potent than the corresponding ester 26.
With respect to the reference compounds tariquidar (EC50 ¼
0.044 mM) and elacridar (EC50 ¼ 0.014 mM), compounds 3 and 8
showed a comparable activity on P-gp, endowed with an EC50
value in the nanomolar range (as above reported) and a P-gp
maximum inhibition (90–95%) at 10mM; the other compounds
were less potent at a different extent, but more selective since
almost all of them were inactive towards both MRP1 and BCRP. As
regard BCRP, although previous SAR studies suggested that the
6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline nucleus
is a requirement for inhibiting both P-gp and BCRP, only six of
these derivatives showed a moderate activity versus BCRP (EC50
ranging from 1.0 to 21.2mM), belonging to the amide and the
ester series. Interestingly, the potent P-gp inhibitor 3 (2,4-dime-
thoxyphenyl amide) was also the most active in BCRP inhibition
(EC50 ¼ 1.0mM). Regarding MRP1 inhibition, all the compounds

























































































































































































Figure 4. In vitro cell growth experiments performed on HT29 (A), HT29/DX cells (B), A549 (C) and A549/DX cells (D) in the presence of compound 3 alone at different
concentrations and in co-administration of 10lM doxorubicin (Doxo) (after the dotted line). Each bar represents the mean± SEM of two experiments performed in trip-
licate. CTR represents the untreated cells, while ctr is the same cell lines treated with 10lM Doxo alone. One-way ANOVA analysis: p< 0.05;p	 0.005; p	 0.0001.
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derivatives, 14 and 16, an EC50 (69.7 and 87.0 mM) could be
defined. It is noteworthy that these two compounds, the 2,3,4-tri-
methoxyphenyl ester 14 and the 2,4-dimethoxyphenyl ester 16,
were active also on BCRP and highly potent vs P-gp, showing a
profile endowed with a low selectivity.
Finally, as regard the P-gp interacting mechanism, all the com-
pounds behaved as not transported substrates (category IIB3),
since they had a BA/AB ratio >2 and were not able to induce ATP
cell depletion47.
On the bases of the obtained results, some very potent com-
pounds were present both among the amide and the ester deriva-
tives; however, the most interesting derivatives (3 and 8)
belonged to amide series. These two compounds showed different
selectivity profiles, since compound 3 was active also on BCRP,
while compound 8 was not.
Co-administration assay
Compounds 3 and 8, endowing with the best P-gp activity profile
in MDCK-MDR1, were tested alone and in co-administration with
the antineoplastic drug, doxorubicin, that, as P-gp substrate, is
usually inactive in tumours overexpressing the pump. A prelimin-
ary study was performed testing the two ligands 3 and 8 alone
and in co-administration with 100 nM and 1 mM doxorubicin, with-
out observing a significant reverting effect (data not shown).
Therefore, we performed the same experiment using doxorubicin
concentration of 10mM.
As depicted in Figure 2, at their EC50 values (around 40 nM),
the two compounds showed a very negligible cytotoxic effect at
48 h of incubation (around 20%), while at higher dose (10 mM)
they reach 30% of cytotoxic effect, compared to untreated cells.
In MDCK cells overexpressing P-gp, doxorubicin alone at 10 mM
did not show cytotoxicity as expected, while the co-administration
with the two compounds at 1 and 10mM was able to rehabilitate
the effect of the antineoplastic agent leading to high cytotoxicity.
In particular, the co-administration of doxorubicin with com-
pounds 3 and 8 at their higher dose (10mM) showed cytotoxicity
values of 77% for 3 and around 50% for 8 (Figure 3).
The efficacy of the compounds was next tested in cancer cell
lines with various levels of P-gp, as the human adenocarcinoma
colon cells (HT29) and non-small cell lung cancer cells (A549) dis-
playing low amount of P-gp, and their resistant counterparts
HT29/DX and A549/DX, with a high amount of P-gp53. In prelimin-
ary assays, we verified that 3 and 8 were not cytotoxic at all the
tested concentration (data not shown).
In HT29 cells, which express low levels of P-gp53, neither 3
(Figure 4) nor 8 (Figure 5) increases the cytotoxicity, measured as
reduced viability, of doxorubicin. By contrast, in the resistant
counterpart HT29/DX, which have higher levels of the transporter,
3 significantly increased the reduction of cell viability induced by


























































































































































































Figure 5. In vitro cell growth experiments performed on HT29 (A), HT29/DX cells (B), A549 (C) and A549/DX cells (D) in the presence of compound 8 alone at different
concentrations and in co-administration of 10lM doxorubicin (Doxo) (after the dotted line). Each bar represents the mean± SEM of two experiments performed in trip-
licate. CTR represents the untreated cells, while ctr is the same cell lines treated with 10lM Doxo alone. One-way ANOVA analysis: p< 0.05; p	 0.005;p	 0.001; p< 0.0001.
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were obtained in A549 and in A549/DX cells, characterised by
high levels of P-gp53. A similar trend was observed also for 8
(Figure 5). More in details, at 10mM, 3 reduced the cell viability of
5% and of 35% in doxorubicin-treated HT29 cells (Figure 4(A)) and
HT29/DX cells (Figure 4(B)), respectively. In A549 and A549/DX
cells it decreased the viability of 25% (Figure 4(C)) and 40%
(Figure 4(D)), respectively. The co-administration with doxorubicin
of compound 8, at 10 mM, reduced cell viability of 10% in HT29
cells (Figure 5(A)), 29% in HT29/DX cells (Figure 5(B)), 25% in A549
cells (Figure 5(C)) and 49% in A549/DX cells (Figure 5(D)).
Notably, HT29 cells had very low/undetectable levels of P-gp54,
while A549 cells had slightly higher levels of P-gp; by contrast, the
corresponding resistant cells display high (HT29/DX) and huge
(A549/DX) amount of P-gp54. The higher toxicity of the combin-
ation of compounds 3 or 8 plus doxorubicin in resistant cells, in
particular in A549/DX subline, confirms that they potentiate cyto-
toxicity of doxorubicin by inhibiting P-gp activity and arousing a
higher intracellular accumulation of the antineoplastic agent in P-
gp expressing cells.
Chemical stability test
Due to the presence of ester or amide groups in the structure of
compounds 1–26, a study aimed to evaluate their susceptibility to
Figure 6. Degradation plots of the ester compound 25 (top) and the corresponding amide derivative 12 (bottom) in PBS (square blue) and human plasma (red tri-
angle) samples. The ester compound 25 suffered a quickly enzymatic hydrolysis (t1/2 about 6min), while the amide derivative 12 was stable over 120min in human
plasma samples. Both the concentration profiles resulted unmodified in PBS solutions.
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spontaneous or enzymatic hydrolysis, was planned. For this pur-
pose, a series of experiments were carried out, adding a known
amount of analyte in both phosphate buffer solution (PBS) and in
human plasma. The samples were analysed by LC-MS/MS method
operating in Multiple Reaction Monitoring (MRM) mode55.
The solution stability of each studied compound was verified
by monitoring the variation of the analyte concentration at differ-
ent incubation times in PBS and human plasma samples. The
processed raw data and the used LC-MS/MS methods are reported
in Supplemental material.
The analyte concentration (1 mM) used during the stability tests
is generally smaller than the corresponding Michaelis–Menten
constant (KM); therefore, the enzymatic degradation rate is
described by a first-order kinetic. Then, by plotting the natural
logarithm of the quantitative data versus the incubation time, a
linear function can be used and its slope represents the degrad-
ation rate (k). Accordingly with the linear function, the half-life (t1/
2) of each tested compound can be calculated as follows:
t1=2 ¼ ln ð0:50lMÞ
.
k
The plots of the natural logarithm of the quantitative data ver-
sus the incubation time of all the studied compounds were ana-
lysed. The obtained results demonstrated that all the compounds
were stable in PBS and most of them also in human plasma. In
particular, all the amide derivatives were not susceptible to the
enzymatic hydrolysis, while the degradation plots of the ester
compounds 15, 16, 18, 24, 25, and 26 in human plasma showed
a significant decay rate (t1/2 values between 6 and 124min). The
calculated half-life values of all tested compounds were reported
in Table 1. The stable compounds showed the k values close to 0;
consequently, for these derivatives, extremely high half-life can be
calculated. Since under the proposed experimental conditions, a
half-life over 240min is not correctly evaluated, it is reasonable to
consider that their half-life values could be equal or greater than
240min. Furthermore, the half-life value of ketoprofene ethylester
(KEE), used as reference compound, demonstrated that the
employed human batch was enzymatically active (t1/2 < 2 h)
55.
The human plasma degradation profiles of the ester compound
25 and its amide homologous 12 are reported as an example in
Figure 6. All degradation plots of the studied compounds are
reported in Supplementary material.
The obtained results indicate that the ester group is more sus-
ceptible to the enzymatic hydrolysis than the corresponding
amide one, since some of the ester derivatives were not stable in
human plasma samples.
Conclusions
In this work, a new series of amide and ester derivatives carrying
a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline scaf-
fold linked to different methoxy-substituted aryl moieties was syn-
thesised. The obtained compounds were evaluated for their P-gp
interaction profile and selectivity towards the two other ABC
transporters, multidrug-resistance-associated protein-1 (MRP-1)
and breast cancer resistance protein (BCRP). Most of the com-
pounds displayed high activity versus P-gp: the presence of an
amide or an ester function did not influence P-gp selectivity and
interacting mechanism. In fact, among both amide and ester
derivatives some very potent compounds could be found, which
resulted in general to be more selective than the reference com-
pounds tariquidar and elacridar. Moreover, in the current case the
derivatives of both series appeared to be substrates belonging to
the category IIB3, showing to interact in the same way with P-gp,
differently from previous findings34.
Noteworthy, the design of the reported series allowed the
identification of two potent P-gp substrates, amides 3 and 8, that
are characterised by different selectivity profiles, since compound
3 was active also on BCRP, while compound 8 was not. These two
aromatic derivatives carry an ortho methoxy substituent, com-
bined with a second methoxy residue in different positions.
The presence of amide or ester groups in the compounds
described in previous work34 did not compromise their chemical
stability to spontaneous or enzymatic hydrolysis, since they
resulted stable in PBS and also in human plasma; interestingly, in
the compounds described in the present work only the amides
resulted stable both in PBS and in human plasma, while the deg-
radation plots of some ester compounds in human plasma
showed a significant decay rate.
Since amide derivatives 3 and 8 showed to be stable and
endowed with the best P-gp activity profile, they were further
tested alone and in co-administration with the antineoplastic drug
doxorubicin in different cancer cell lines with various levels of P-
gp. The compounds showed a significant sensitising activity
towards doxorubicin in cell models that are similar to clinically
observed doxorubicin-resistant cancers, indicating that the chemo-
sensitizing effects were due to the inhibition of P-gp.
In summary, the design of the reported series allowed the
identification of two potent P-gp substrates, stable both in PBS
and in human plasma and able to rehabilitate the effect of the
antineoplastic agent doxorubicin in different cancer cell lines.
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Chemical stability data 
 
Instrumental 
The LC-MS/MS analysis was carried out using a Varian 1200L triple quadrupole system (Palo Alto, 
CA, USA) equipped by two Prostar 210 pumps, a Prostar 410 autosampler and an Elettrospray 
Source (ESI) operating in positive ions mode. Raw-data were collected and processed by Varian 
Workstation Vers. 6.8 software. G-Therm 015 thermostatic oven was used to keep the samples at 
37 °C during the degradation tests. Eppendorf microcentrifuge 5415D was employed to centrifuge 
plasma samples. 
Standard solutions and calibration curves 
Stock solutions of analytes and verapamil hydrochloride (ISTD) were prepared in acetonitrile at 1.0 
mg mL-1 and stored at 4 °C. Working solutions of each analyte were freshly prepared by diluting 
stock solutions up to a concentration of 10 μM and 1 μM (working solution 1 and 2 respectively) in 
mQ water: acetonitrile 80:20 (v/v) solution. The ISTD working solution was prepared in acetonitrile 
at 60 ng mL-1 (ISTD solution).  
A six levels calibration curve was prepared by adding proper volumes of working solution of each 
analyte to 300 μL of ISTD solution. The obtained solutions were dried under a gentle nitrogen 
stream and dissolved in 1.0 mL of 10 mM of formic acid in mQ water: acetonitrile 70:30 (v/v) 
solution. Final concentrations of calibration levels were: 0, 0.05, 0.10, 0.20, 0.50, 0.75 and 1.00 M 
of analyte in the sample.  
All calibration levels were analysed six times by the appropriate LC-MS/MS method. 
LC-MS/MS method 
The chromatographic parameters employed to analyse the samples were tuned to minimize the run 
time and were reported as follows: 
- column, Pursuit C18 length = 30 mm; internal diameter = 2mm; particle size = 3 μm purchased 
from Agilent Technologies (Palo Alto, CA, USA) 
- acidic mobile phase, composed by 5 mM of ammonium formate and 10mM of formic acid in mQ 
water: acetonitrile 90:10 (v/v) solution (solvent A), 5 mM of ammonium formate and 10mM of 
formic acid in mQ water: acetonitrile 10:90 (v/v) solution (solvent B).  
- flow rate and the injection volume were 0.25 mL min-1 and 5 μL respectively. 
The elution gradient is shown in Table S1. 
The analyses were acquired in product ion scan, resonant excitation mode, parameters are reported 
in Table S2, using Nitrogen as collision gas. 
 
Table S1: Elution gradient of mobile phase used for LC-MS/MS analyses 
 
















(m/z) [CE (V)] 
Qualification ion 
(m/z) [CE (V)] 
KEE 283 209 [15] 209 [30] 
1 507 195 [35] 314 [30] 
2 447 135 [45] 254 [30] 
3 477 165 [45] 284 [30] 
4 477 165 [40] 284 [30] 
5 477 165 [45] 284 [30] 
6 467 155 [50] 274 [30] 
7 497 185 [40] 304 [30] 
8 527 215 [45] 334 [30] 
9 418 225 [30] 254 [25] 
10 448 136 [50] 255 [30] 
11 419 226 [40] 255 [30] 
12 449 256 [35] 285 [35] 
13 498 186 [50] 334 [35] 
14 508 195 [40] 179 [35] 
15 448 135 [35] 179 [30] 
16 478 165 [40] 179 [35] 
17 478 165 [40] 179 [30] 
18 478 165 [40] 179 [35] 
19 468 155 [40] 179 [30] 
20 498 185 [40] 179 [35] 
21 528 215 [40] 179 [40] 
22 419 255 [30] 179 [30] 
23 449 136 [45] 285 [35] 
24 420 256 [30] 227 [40] 
25 450 179 [30] 286 [35] 




Linearity and LOD 
Calibration curves of analytes were obtained by plotting the peak area ratios (PAR), between 
quantitation ions of analyte and ISTD, versus the nominal concentration of the calibration solution. 
A linear regression analysis was applied to obtain the best fitting function between the calibration 
points.  
The precision was evaluated through the relative standard deviation (RSD%) of the quantitative 
data of the replicate analysis of highest level of calibration curves. 
In order to obtain reliable LOD values, the standard deviation of response and slope approach was 
employed. The estimated standard deviations of responses were obtained by the standard deviation 
S30 
 
of y-intercepts (SDY-I) of regression lines. The obtained linear regressions, the linearity 
coefficients, precision and the estimated LOD values for each analyte are reported in Table S3. 
 












1  1.88 0.008 0.998 1.4% 0.05 
2 2.15 0.002 0.999 5.0% 0.07 
3 2.02 -0.010 0.997 0.8% 0.08 
4 2.09 0.005 0.999 5.1% 0.09 
5 4.11 -0.003 0.996 1.2% 0.05 
6 1.83 -0.005 0.997 2.6% 0.05 
7 3.92 0.007 0.999 1.1% 0.06 
8 2.52 -0.011 0.999 1.4% 0.05 
9 0.26 0.012 0.999 2.8% 0.09 
10 0.46 0.005 0.999 6.5% 0.05 
11 1.56 0.009 0.999 1.6% 0.04 
12 0.75 0.015 0.998 2.0% 0.06 
13 0.65 0.013 0.999 3.0% 0.05 
14 4.77 0.007 0.999 0.5% 0.08 
15 2.73 -0.004 0.999 4.5% 0.05 
16 2.06 -0.008 0.999 1.9% 0.05 
17 3.67 -0.011 0.999 0.3% 0.07 
18 4.85 0.007 0.999 1.9% 0.08 
19 3.15 0.001 0.998 0.8% 0.06 
20 3.93 -0.005 0.996 2.0% 0.05 
21 2.53 0.003 0.999 2.8% 0.07 
22 0.33 0.007 0.999 4.7% 0.08 
23 0.91 -0.012 0.997 1.5% 0.09 
24 0.13 -0.009 0.999 7.0% 0.07 
25 0.55 0.009 0.998 1.0% 0.05 





Solution stability profiles  
The solution stability profiles in PBS and human plasma were obtained by monitoring the variation 
of analyte concentration at different incubation times. They are reported in Figures S1-S26. 
 
Figure S1: Degradation plots of 1 in PBS (blue square) and human plasma (red triangle). 
 




Figure S3: Degradation plots of 3 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S5: Degradation plots of 5 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S7: Degradation plots of 7 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S9: Degradation plots of 9 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S11: Degradation plots of 11 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S13: Degradation plots of 13 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S15: Degradation plots of 15 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S17: Degradation plots of 17 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S19: Degradation plots of 19 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S21: Degradation plots of 21 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S23: Degradation plots of 23 in PBS (blue square) and human plasma (red triangle). 
 
 





Figure S25: Degradation plots of 25 in PBS (blue square) and human plasma (red triangle). 
 
 










Figure S27. Immunoblotting analysis of P-gp, MRP1 and BCRP expression in MDCK, MDCK-
MDR1, MDCK-MRP1 and MDCK-BCRP cells. Tubulin was used as control of equal protein 
loading. 
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